Key points are not available for this paper at this time.
Upregulation of IL-6 has been associated with worse prognosis in COVID-19 patients. Impact on IL-6 signalling has mostly been limited to clinical outcomes in IL-6 receptor antagonist trials.
Gottlieb et al. (Mon,) studied this question.